Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Coherus Oncology's price to sales ratio was 1.8× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 0.5× to 6.8×, with a median of 2.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | −2.7 |
| 2025 | Dec 31, 2025 | 4.4× | +3.0 |
| 2024 | Dec 31, 2024 | 1.4× | −0.3 |
| 2023 | Dec 29, 2023 | 1.7× | −0.9 |
| 2022 | Dec 30, 2022 | 2.6× | −0.8 |
| 2021 | Dec 31, 2021 | 3.4× | +0.5 |
| 2020 | Dec 31, 2020 | 2.9× | −2.9 |
| 2019 | Dec 31, 2019 | 5.7× | −459.6 |
| 2018 | Apr 30, 2018 | 465.3× | +283.4 |
| 2017 | Dec 29, 2017 | 181.9× | +175.9 |
| 2016 | Dec 30, 2016 | 6.0× | −23.0 |
| 2015 | Dec 31, 2015 | 29.0× | +26.1 |
| 2014 | Dec 31, 2014 | 2.9× | – |
See a number that looks wrong?